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INTRODUCTION 
Oral administration is the most convenient and preferred means of any drug 
delivery to the systemic circulation. Oral controlled release drug delivery have 
recently been of increasing interest in pharmaceutical field to achieve improved 
therapeutic advantages, such as ease of dosing administration, patient compliance 
and flexibility in formulation. Drugs that are easily absorbed from gastrointestinal 
tract (GIT) and have short half-lives are eliminated quickly from the systemic 
circulation. Frequent dosing of these drugs is required to achieve suitable 
therapeutic activity. To avoid this limitation, the development of oral sustained-
controlled release formulations is an attempt to release the drug slowly into the 
gastrointestinal tract (GIT) and maintain an effective drug concentration in the 
systemic circulation for a long time. [1] 
 
The de novo design of an oral controlled drug delivery system (DDS) should 
be primarily aimed at achieving more predictable and increased bioavailability of 
drugs. However, the development process is precluded by several physiological 
difficulties, such as an inability to restrain and localize the DDS within desired 
regions of the (GIT) and the highly variable nature of gastric emptying process. It 
can be anticipated that, depending upon the physiological state of the subject and 
the design of pharmaceutical formulation, the emptying process can last from a few 
minutes to 12 hrs. This variability, in turn, may lead to unpredictable bioavailability 
and times to achieve peak plasma levels, since the majority of drugs are 
preferentially absorbed in the upper part of the small intestine. Furthermore, the 
relatively brief gastric emptying time (GET) in humans, which normally averages 2–
3 hrs through the major absorption zone (stomach or upper part of the intestine), 
can result in incomplete drug release from the (DDS) leading to diminished efficacy 
of the administered dose. Thus, control of placement of a (DDS) in a specific region 
of the (GIT) offers numerous advantages, especially for drugs exhibiting an 
absorption window in the (GIT) or drugs with a stability problem. These 
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considerations have led to the development of oral controlled-release (CR) dosage 
forms possessing gastric retention capabilities. [2] 
After oral administration, such a drug delivery system would be retained in 
the stomach and release the drug in a controlled manner, so that the drug could be 
supplied continuously to its absorption sites in the (GIT). Gastro-retentive drug 
delivery is an approach to prolong gastric residence time, thereby targeting site-
specific drug release in the upper gastrointestinal tract (GIT) for local or systemic 
effects. 
 
BASIC GASTROINTESTINAL TRACT PHYSIOLOGY: [3] 
 
Stomach Physiology: 
Anatomically the stomach is divided into 3 regions: fundus, body, and 
antrum (pylorus). The proximal part made of fundus and body acts as a reservoir 
for undigested material, whereas the antrum is the main site for mixing motions and 
act as a pump for gastric emptying by propelling actions.  
 
Fig. 1: Physiology of stomach 
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delayed resulting in slowdown of gastric emptying rate. Scintigraphic studies 
determining gastric emptying rates revealed that orally administered controlled 
release dosage forms are subjected to basically 2 complications, that of short gastric 
residence time and unpredictable gastric emptying rate. 
 
FACTORS AFFECTING GASTRIC RETENTION: [5] 
                 
The gastric retention time (GRT) of dosage form is controlled by several 
factors, which affect their efficacy as a gastroretentive system. 
• Density – GRT is a function of dosage form buoyancy that is dependent on 
the density. 
• Size – Dosage form units with a diameter of more than 9.5mm are reported to 
have an increased GRT. 
• Shape of dosage form – Tetrahedron and ring-shaped devices with a flexural 
modulus of 48 and 22.5 kilopounds per square inch (KSI) are reported to 
have better GRT. 90% to 100% retention at 24 hours compared with other 
shapes. 
• Fed or unfed state – Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric cycle 
(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer. 
• Nature of meal – Feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release. 
• Caloric content – GRT can be increased by four to 10 hours with a meal that 
is high in proteins and fats. 
• Frequency of feed – The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
Introduction 
 
Dept of Pharmaceutics, Annai Veilankanni’s Pharmacy College , Chennai.  Page 5 
 
• Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared 
with their age and race-matched female counterparts (4.6±1.2 hours), 
regardless of the weight, height and body surface. 
• Age – Elderly people, especially those over 70, have a significantly longer 
GRT. 
• Posture – GRT can vary between supine and upright ambulatory states of the 
patient. 
• Concomitant drug administration– Anticholinergics like Atropine and 
Propantheline, Opiates like Codeine and Prokinetic agents like 
Metoclopramide and Cisapride. 
• Biological factors – Diabetes and Crohn’s disease. 
 
TYPES OF GASTRORETENTIVE DOSAGE FORMS:  
1. Floating drug delivery systems (FDDS) 
• Effervescent. 
• Non effervescent. 
2. High density systems. 
3. Swelling or Expandable systems. 
4. Bioadhesive or Mucoadhesive systems. 
Fig.2: Various Gastro retentive Dosage forms 
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b) Intra gastric bilayer floating tablets: These are also tablets which contain 
two layers, namely immediate release layer which is required to maintain the 
loading dose and sustained release layer which releases drug for sustained 
period. 
c) Multiple unit type floating pills: These systems consist of effervescent 
agents inside and swelling membrane in outer layer. When it is placed in 
dissolution medium it swells, subsequently the density is reduced which 
makes it suitable for floating. 
B. Volatile liquid containing systems: The concept involved in this system is 
sustaining the gastric retention by incorporating an inflatable chamber. This 
chamber contains a volatile liquid e.g. ether, cyclopentane, that gasifies at body 
temperature. 
 
2. Non-effervescent Systems: 
These systems form gel or swells when it contacts gastric fluids. This is due to 
the presence of hydrocolloids. Due to the air entrapment in swollen matrix the 
density of this system becomes less than one, so that it floats.  
 The major requirements for floating drug delivery system are: 
• It should release contents slowly to serve as a reservoir. 
• It must maintain specific gravity lower than gastric contents (1.004 – 1.01 
gm/cm3). 
• It must form a cohesive gel barrier. 
 
Advantages of Floating Drug Delivery:  
¾ Improved bioavailability. 
¾ Reduced dose and dosing frequency. 
¾ Minimized fluctuation of drug concentration in blood. 
¾ Targeting of drugs. 
¾ Local action can be achieved in GIT e.g. Antacids. 
¾ Reduced side effects. 
¾ Can be used for wide range of drugs. 
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¾ Sustained release can be achieved. 
¾ Safest route of administration. 
¾ Economic. 
 
Limitations of Floating Drug Delivery: [4] 
¾ Should be administered with plenty of water. 
¾ Drugs with solubility or stability problem in GIT can’t be administered. 
¾ Drugs such as Nifedipine which is well absorbed along the entire GIT and 
which undergoes first pass metabolism, may not be desirable. 
¾ Drugs which are irritant to gastric mucosa are not suitable. 
¾ These systems do not offer significant advantages over the conventional 
dosage forms for drugs which are absorbed throughout the gastrointestinal 
tract. 
 
Application of Floating Drug Delivery Systems: [7] 
Floating drug delivery offers several applications for drugs having poor 
bioavailability because of the narrow absorption window in the upper part of the 
gastrointestinal tract. It retains the dosage form at the site of absorption and thus 
enhances the bioavailability. These are summarized as follows. 
1. Sustained Drug Delivery: These systems can remain in the stomach for long 
periods and hence can release the drug over a prolonged period of time. The 
problem of short gastric residence time encountered with an oral CR 
formulation hence can be overcome with these systems.  
2.  Site-Specific Drug Delivery: These systems are particularly advantageous for 
drugs that are specifically absorbed from stomach or the proximal part of the 
small intestine.  
3. Absorption Enhancement: Drugs that have poor bioavailability because of 
site specific absorption from the upper part of the gastrointestinal tract are 
potential candidates to be formulated as floating drug delivery systems, 
thereby maximizing their absorption. 
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POTENTIAL DRUG CANDIDATES FOR FLOATING DRUG DELIVERTY 
SYSTEMS (FDDS): [1] 
 
1) Drugs those are locally active in the stomach: e.g. misroprostol, 
antacids etc. 
2) Drugs that have narrow absorption window in gastrointestinal tract 
(GIT): e.g.   L-DOPA, para aminobenzoic acid, furosemide, riboflavin 
etc. 
3) Drugs those are unstable in the intestinal or colonic environment: e.g. 
captopril, ranitidine, metronidazole. 
4) Drugs that disturb normal colonic microbes: e.g. antibiotics against 
Helicobacter pylori. 
5) Drugs that exhibit low solubility at high pH values: e.g. diazepam, 
chlordiazepoxide, verapamil HCl. 
 
 
 
 CINITAPRIDE  :       
Cinitapride1‐2,chemically4‐amino‐N‐[3‐(Cyclohexan‐1‐yl‐methyl)‐4‐piperidinyl]‐2‐e
thoxy‐5‐nitrobenzamide has the molecular formula C21H30N4O4 and molecular 
weight 402.49 g.mol‐1 .Cinitapride is a drug that has against action to the 
serotoninergic 5‐HT2 and D2 dopaminergic receptors that has been indicated in the 
gastro esophageal reflux and in the functional disorders of gastrointestinal motility 
treatment.  
                 The therapeutic effect of cinitapride lies on the capacity of increasing 
lower esophageal sphincter tone and has strong gastro kinetic activity, which 
generates significant increases in the gastric emptiness; besides, through the 
serotoninergic system it stimulates the intestinal activity. The use of cinitapride is 
efficient and safe in treatment of patients with disorders in the gastric emptiness 
related to gastro esophageal reflux and functional dyspepsia as well as in individuals 
that present irritable bowel syndrome with constipation and abdominal pain.  
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                   Literature survey reveals a polarographic3 method for its determination. 
Further, a fast, sensitive and selective method for measuring plasma cinitapride 
using LC‐MS/MS with positive ion electrospray ionization using multiple reaction‐ 
monitoring (MRM) mode to quantify cinitapride in human plasma using respridone 
as the internal standard is also reported 4.To best of our knowledge, there is no 
work in the literature reported about the spectrophotometric method for the 
analysis of cinitapride in biological fluids or pharmaceutical formulations. Hence, 
the authors has made an attempt to develop few simple and rapid 
spectrophotometric methods 5‐7 for the estimation of cinitapride [8] 
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• Roy et al. 2008[9] described rapid, sensitive and specific method to 
quantitify cinitapride in human plasma using risperidone as the internal 
standard. Sample preparation involved simple solid phase extraction 
procedure. Plasma concentrations of cinitapride were determined by LC-
MS/MS with a LOQ (limit of quantification) of 20.118 pg mL-1 that 
allowed an appropriate characterization of the pharmacokinetic profile of 
cinitapride at the therapeutic dose. The method was successfully applied 
to the bioequivalence study of cinitapride tablet (1.0 mg) administered as 
a single oral dose. 
 
• Sangeetha et al [10] design and evaluate oral sustained release tablet of 
lamotrigine using polymer such as HPMC K 4M, HPMC K 100M and 
methocel E50 LV at 15%, 25%, and 35% Concentration range.  In vitro 
release profile was studied using HPMC K4M, HPMC K 100M and 
methocel E50 LV at three different concentration. The percentage 
cumulative amount of drug release was found to be 82.72% in 12 hrs, 
70.69% in 12hrs and 97.80% in 4hrs respectively for the entire batch at 
15% polymer concentration. The study proves that fluctuation in the drug 
release is overwhelmed when lamotrigine is administered in the form of 
SR tablet. 
 
 
• DESIGN AND EVALUATION OF LAMOTRIGINE ORAL SUSTAINED 
RELEASE TABLETS[11] 
The purpose of writing this review on floating drug delivery systems 
(FDDS) was to compile the recent literature with special focus on the 
principal mechanism of floatation to achieve gastric retention. The recent 
developments of FDDS including the physiological and formulation 
variables affecting gastric retention, approaches to design single-unit and 
multiple-unit floating systems, and their classification and formulation 
aspects are covered in detail. This review also summarizes the in vitro 
techniques, in vivo studies to evaluate the performance and application of 
floating systems, and applications of these systems. These systems are 
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useful to several problems encountered during the development of a 
pharmaceutical dosage form. 
 
 
 
• Anuradha K. Salunkhe et.al (2011); [12] prepared and evaluated a floating 
pulsatile drug delivery system of metoprolol tartrate. The prepared 
floating pulsatile delivery system consisted of three different parts: a core 
tablet, containing the active ingredient, an erodible outer shell and a top 
cover buoyant layer. The rapid release core tablet (RRCT) was prepared 
by using superdisintegrants along with active ingredient. Dry coating of 
optimized RRCT was done by using different grades of hydroxy propyl 
methyl cellulose (HPMC) E5, E15, and E50 and upper most buoyant layer 
was prepared with HPMC K15M and sodium bicarbonate. Developed 
formulations were evaluated for their physical characteristics, drug 
content, in-vitro disintegration time, in-vitro drug release profile (lag 
time), floating lag time, floating time and in-vivo X-ray study. On the basis 
of these evaluation parameters it was found that optimized floating 
pulsatile release formulation (FPRT) showed floating lag time of 4 min. 
 
• Vikrant K. Nikam et.al (2011); [13] designed and evaluated verapamil HCL 
floating controlled release gastroretentive tablets using different 
hydrocolloid polymers including Carbopol, Hydroxy propyl methyl 
cellulose, and Xanthan gum incorporated for gel forming agent by direct 
compression technology. The tablets were evaluated for the 
physicochemical parameters such as weight variation, thickness, friability, 
hardness, drug content, in-vitro buoyancy studies, in-vitro dissolution 
studies. The prepared tablets exhibited satisfactory physico-chemical 
characteristics. Tablet buoyancy was achieved by adding an effervescent 
mixture of sodium bicarbonate and anhydrous citric acid. The in-vitro 
dissolution studies were carried out in a USP XXII apparatus II in 0.1N 
HCl. All the gastroretentive tablets showed good in-vitro buoyancy. The 
selected tablets containing Xanthan gum released approximately 94.43% 
drug in 24 h, while the buoyancy lag time was 25.8 ± 4.2 second and the 
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tablet remained buoyant for > 24 h. Zero order and non-Fickian release 
transport was confirmed as the drug release mechanism for the selected 
tablets.   
 
 
 
• Liandong Hu et.al (2011); [14] developed dextromethorphan hydrobromide 
sustained-release (DMB-SR) tablets using floating technique to prolong 
the gastric residence time and compared their pharmacokinetic behavior 
with conventional sustained release tablets. DMB-SR floating tablets were 
prepared employing hydroxy propyl methyl cellulose (HPMC) as 
hydrophilic gel material, sodium bicarbonate as gas-generating agent and 
hexadecanol as floating assistant agent. An orthogonal experiment design 
method was used to select the optimized formulation. The floating tablets 
were evaluated for uniformity of weight, hardness, friability, drug 
content, floating characteristics, in-vitro release and in-vivo 
bioavailability. The optimized tablets were prepared with HPMC K4M 25 
mg, sodium bicarbonate 20 mg and hexadecanol 18 mg. The prepared 
tablets could float within 3 min and maintain for more than 24 h. The data 
of physical parameters were all lie within the limits. Drug release at 12 h 
was more than 85%. The comparative pharmacokinetic study was 
performed by administration of the DMB-SR floating tablets and 
conventional DMB-SR tablets. The area under curve of plasma 
concentration–time (AUC) of floating tablets was slightly higher than that 
of reference tablets, Tmax was prolonged apparently. The results showed 
the floating tablets are a feasible approach for the sustained-release 
preparation of drugs, which have limited absorption sites in the stomach. 
 
• Nanjan Sockan Ganesh et.al (2011); [15] prepared floating drug delivery 
system of Ketoprofen using variable concentration of polymers (HPMC 
K4M and Ethyl cellulose). Formulations were evaluated for physico-
chemical, pre-formulation parameters and formulation parameters, in-
vitro buoyancy studies, in-vitro release studies and results obtained in in-
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vitro release studies were plotted in different models of data treatment 
(Zero Order, First Order, Higuchi’s and Peppa’s). Compatibility studies 
were performed using FTIR, there was no interaction between Ketoprofen 
and the polymers used. The measured hardness of tablets of each batch 
ranged between 4.3 to 6.4 kg/cm² which ensured good handling 
characteristics of all batches. The percentage drug content for all 
formulations ranged from 97.04% to 99.69% of Ketoprofen which 
complies with official specifications. All the batches were subjected to in-
vitro release studies at 0.1N HCL (pH 1.2) and Phosphate buffer (pH 6.8). 
The best release was observed with formulation containing (3:1 ratio of 
HPMC K4M and Ethyl cellulose). 
 
• Pramod Patil et.al (2011); [16] developed floating tablets of ofloxacin which 
were designed to prolong the gastric residence time after oral 
administration. Ofloxacin floating tablets were prepared by wet 
granulation method incorporating natural polymers like guar gum, locust 
bean gum, either alone or in combination with HPMC K100M as swelling 
polymers, with sodium bicarbonate as gas generating agent and were 
evaluated for parameters such as Weight variation, Hardness, Friability, 
Drug content, Swelling index, in-vitro buoyancy study, in-vitro drug 
release study. All the formulation showed compliance with pharmacopieal 
standards. The selected best formulations were checked for stability as per 
ICH guidelines. These results indicated that the selected formulations 
were stable. The drug release profile of the best formulations was well 
controlled and uniform throughout the dissolution studies. The drug 
release of optimized formulation follows the Higuchi kinetic model, and 
the mechanism is found to be non-Fickian/anomalous according to 
Korsmeyer–Peppas equation. 
 
• M.I. Tadros (2010); [17] developed a gastroretentive controlled release drug 
delivery system of Ciprofloxacin hydrochloride with swelling, floating, 
and adhesive properties. Tablet formulations were designed using 
hydroxy propyl methyl cellulose (HPMC K15M) and/or sodium alginate 
(Na alginate) as release-retarding polymer(s) and sodium bicarbonate 
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(NaHCO3) or calcium carbonate (CaCO3) as a gas former. Swelling ability, 
floating behavior, adhesion period and drug release studies were 
conducted in 0.1 N HCL (pH 1.2) at 37 ± 0.5 ˚C. The tablets showed 
acceptable physicochemical properties. Drug release profiles of all 
formulae followed non-Fickian diffusion. Statistical analyses of data 
revealed that tablets containing HPMC K15M (21.42%, w/w), Na alginate 
(7.14%, w/w) and NaHCO3 (20%, w/w) or CaCO3 (20%, w/w) were 
promising systems exhibiting excellent floating properties, extended 
adhesion periods and sustained drug release characteristics. Both 
formulae were stored at 40 ˚C/75% RH for 3 months according to ICH 
guidelines. Formulation showed better physical stability. Abdominal X-
ray imaging of formulation, loaded with barium sulfate, in six healthy 
volunteers revealed a mean gastric retention period of 5.50 ± 0.77 h. 
 
• Kar et.al (2010); [18] prepared and characterized gastro retentive floating 
tablets of Cefuroxime Axetil. Hydrophilic polymers such as HPMC K15M 
and HPMC E5LV were used for its gel forming and release controlling 
properties. Sodium bicarbonate was incorporated as gas generating agent 
and Sodium Laurayl Sulfate (SLS) was used as solubility enhancer. The 
effects of gel forming agent (HPMC K15M and HPMC E5LV) and 
surfactant on drug release profile and floating properties were 
investigated. It has been observed that release characteristics were 
decreased with high viscous polymer due to increased tortuosity and 
length of drug diffusion path. Significant difference in release rate was 
found in different concentration of SLS. The release mechanisms were 
explored and explained with zero order, first order, Higuchi, Korsmeyer 
and Hixon-Crowell equations. The release rate, extent and mechanisms 
were found to be governed by the content of polymer. It was found that 
polymer content and amount of floating agent significantly affected the 
time required for 50% of drug release (T50%), Mean dissolution time 
(MDT), release rate constant, and diffusion exponent (n).Kinetic modeling 
of dissolution profiles revealed that the drug release mechanism could 
range from diffusion controlled to case II transport, which was co-
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dominated by both diffusion and polymer erosion in the release 
mechanism. 
 
• Ramanathan et.al (2010); [19]  fabricated a hydro-dynamically balanced 
system (HBS) of Mefenamic Acid. The different viscosity grades of 
hydroxy propyl methyl cellulose polymer like HPMC K100, HPMC K4M, 
HPMC KV600, and HPMC K50 was incorporated as hydrophilic 
swellable polymers for preparing matrix-floating tablets. Sodium 
bicarbonate was incorporated as a gas-generating agent. The prepared 
floating tablets were evaluated for the physical parameters like thickness, 
hardness, friability, drug content, floating lag time, floating time and in-
vitro dissolution studies. The mechanism of drug release was anomalous 
type and depends upon the viscosity of polymers, which was mainly 
concluded as the major controlling factor for the drug release. The results 
showed that the formulation containing Drug: HPMC KV600 in the ratio 
of 1:0.5 is suitable for the formulation of gastro-retentive floating tablets 
of mefenamic acid. 
 
• Margret Chandira et.al (2010); [20] formulated floating tablets of Itopride 
hydrochloride a gastroprokinetic drug using an effervescent approach for 
gastroretentive drug delivery system. Floating tablets were fabricated; 
using direct compression method; containing polymers HPMC K100M, 
HPMC K15M and Carbopol 934 P, along with gas generating agent 
sodium bicarbonate and citric acid. The addition of Carbopol aided in the 
reduction of the drug dissolution due to their hydrophobic nature. The 
concentration of these agents was also optimized to get desired controlled 
release of drug. The floating tablet formulations were evaluated for 
physical characterization, assay, swelling index, in‐vitro drug release, 
hardness, friability and weight variation. The results indicated that gas 
powered floating tablets of Itopride hydrochloride containing 125 mg 
HPMC K100M, 40 mg HPMC K15M, and 40 mg Carbopol provides a 
better option for 24 hours release action and improved bioavailability. 
The drug release pattern of this optimized formulation was found to be 
non‐fickian diffusion mechanism. The accelerated stability studies, at 
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40˚C / 75% RH, of the optimized formulation were carried out for one 
month and no significant change was observed. 
 
• Pare et.al (2008); [21] developed Amlodipine besylate effervescent floating 
tablets by employing hydrophilic polymers (HPMC K100M, HPMC 
K15M) and hydrophobic polymer (carbopol 934P) along with effervescing 
agent sodium bicarbonate and citric acid. The formulations were 
evaluated for various physical parameters, buoyancy studies, dissolution 
parameters and drug release mechanisms. Formulations showed 
maximum floating time of 24 hours and gave slow and maximum drug 
release of Amlodipine besylate spread over 24 hours whereas Amlodipine 
besylate released from marketed tablet was rapid and maximum within 12 
hours. 
 
• Sanjay S. Patel et.al (2006); [22] designed floating dosage form containing 
clarithromycin for the treatment of Helicobacter pylori. Tablets 
containing hydroxyl propyl methyl cellulose (HPMC), drug and different 
additives were compressed using wet granulation and D-optimal design 
technique. The study showed that tablet composition and mechanical 
strength have great influence on the floating properties and drug release. 
Incorporation of gas-generating agent together with polymer improved 
drug release, besides optimal floating (floating lag time <30 s; total 
floating time >10 h). The drug release was sufficiently sustained (more 
than 8 h) and anomalous diffusion as well as zero-order was confirmed. 
The optimized formulation was obtained using 62.5% clarithromycin, 
4.95% HPMC K15M, 18.09% HPMC K4M, 12.96% sodium bicarbonate 
which gave floating lag time < 30 s with a total floating time > 10 h, in-
vitro release profile very near to the target in-vitro release profile and 
follows anomalous diffusion as well as zero order pattern of release. 
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AIM AND OBJECTIVE 
 
AIM: 
                To design, formulate & evaluate floating tablets containing Cinitapride 
based on floating technique in order to increase gastric retention time for 
enhancing site-specific absorption in the stomach or upper parts of the small 
intestine as well as to produce controlled release of the drug for a longer time. 
To evaluate the influence of preparative parameters and its effect on drug 
release, The floating ability of the formulation and the release mechanism on the 
basis of various kinetic models. 
              
OBJECTIVES : 
     To design of sustained release dosage form of Cinitapride that will help in 
releasing only small quantities of drug over a prolonged period of time. 
     To study the effect of type of polymers and polymer concentration on 
release profiles of controlled release cinitapride formulations. 
     To study the different types of schemes on release profiles of controlled 
release Cinitapride formulations. 
To arrive at better formulation based on comparison amongst the studied 
ones. 
To perform stability studies as per ICH guidelines. 
           
Plan of Work 
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PLAN OF WORK 
 
1. Literature review. 
2. Pre-formulation studies. 
3. Preparation of floating tablets of Cinitapride. 
4. Evaluation of tablets for: 
a. Hardness 
b. thickness 
c. Friability 
d. Weight variation 
e. Assay 
f. Dissolution studies. 
5. Kinetic models analysis: 
a. First order 
b. Zero order 
6. Stability studies. 
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TOXICITY 
The symptoms of overdose include drowsiness, confusion and extrapyramidal 
effects. 
 
BIOAVAILABILITY: 50 – 95%  
 
HALF LIFE:  3-5 h during the first 8 h and a residual half-life greater than 15 h 
thereafter. 
 
PHARMACOKINETICS 
Pharmacokinetic studies in man following oral and intramuscular administration 
have been made using doses substantially higher than the therapeutic dose due to 
the absence of a sufficiently sensitive analytical method for the detection of 
plasma concentrations following very low doses of cinitapride. The absorption of 
cinitapride (12mg) following oral administration was rapid, with peak levels 
being achieved 2 h after dosing; absorption following intramuscular 
administration (4mg) was even more rapid,with peak levels (50% more that oral 
levels)  being achieved 1 h after dosing. 
The elimination profile in man was similar by either route of administration, 
with a half- 
life of some 3-5 h during the first 8 h and a residual half-life greater than 15 h 
thereafter. 
The plasma levels during this slow phase were, however, negligible and the 
overall 
pharmacokinetic profile is indicative of 3 time’s daily dosing schedule being the 
most 
appropriate. Since the urinary 24-h excretion of cinitapride and its two major 
metabolites 
(principally the de-alkylated product) was no greater than 7% of the 
administered dose, this is obviously only a minor elimination pathway 
 
PHARMACODYNAMICS 
Drug Profile 
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These drugs may increase acetylcholine concentrations by antagonizing the M1 
receptor which inhibits acetylcholine release, or by inhibiting the enzyme 
acetylcholinesterase which metabolizes acetylcholine. Higher acetylcholine levels 
increase gastrointestinal peristalsis and further increase pressure on the lower 
esophageal sphincter, thereby stimulating gastrointestinal motility, accelerating 
gastric emptying, and improving gastro-duodenal coordination. 
The 5-HT4 receptor is thought to play a significant role in both the physiology 
and pathophysiology of GI tract motility.[2] Therefore, 5-HT4 receptors have 
been identified as potential therapeutic targets for diseases related to GI 
dysmotility such as chronic constipation. Some of these prokinetic agents, such as 
mosapride and cisapride, classic benzamides, have only moderate affinity for 
5HT4 receptors. In recent years, it has become clear that the selectivity profile is 
a major determinant of the risk-benefit profile of this class  
DOSE AND ADMINISTRATION 
Administrated by oral route 
Adult: 1mg  tab t,i,d   
 
USES 
Delayed gastric emptying,  
Gastro-esophageal reflux disease,  
Non-ulcer dyspepsia.  
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                                               HYPROMELLOSE[25] 
Nonproprietary names: 
 BP : Hypromellose  
 JP : Hydroxypropyl methylcellulose  
 PhEur : Hypromellosum 
USP : Hypromellose 
Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropyl cellulose; Metolose; 
Tylopur. 
Chemical name and CAS registry number: 
Cellulose 2- hydroxypropyl methyl ether [9004-65-3] 
Molecular weight: 
Molecular weight is approximately 10,000-1,500,000.  
Structural formula: 
 
 
                            Where R is H, CH3, or CH3CH (OH) CH2 
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Functional category: 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder and viscosity increasing agent. 
Applications in pharmaceutical formulation or technology: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as matrix for use in extended-release tablet formulations.  
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes.  
High-viscosity grades may be used to retard the release of drugs from a 
matrix at levels of 10-80% w/w in tablets and capsules. Depending upon the viscosity 
grade, concentrations of 2-20% w/w are used for film-forming solutions to film-coat 
tablets.  Lower-viscosity grades are used in aqueous film-coating solutions, 
while higher-viscosity grades are used with organic solvents. Hypromellose at 
concentrations between 0.45-1.0% w/w may be added as a thickening agent to 
vehicles for eye drops and artificial tear solutions.  
Typical  Properties: 
 Acidity/alkalinity      :          pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 
 Density (bulk)           :          0.341 g/cm3 
 
 Density (tapped)       :          0.557 g/cm3 
 
 Density (true)            :          1.326 g/cm3 
 
 Melting Point            :          browns at 190 – 200°C; chars at 225 – 
230°C 
    Glass transition temperature is 170 - 
180o C 
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Table 5.3: Various grades of hypromellose 
 
Methocelproduct USP 28 designation Nominal viscosity (mPa s)
Methocel K100 Premium LVEP 2208 100 
Methocel K4M Premium 2208 4000 
Methocel K15M Premium 2208 15 000 
Methocel K100M Premium 2208 100 000 
Methocel E4M Premium 2910 4000 
Methocel F50 Premium 2906 50 
Methocel E10M Premium CR 2906 10 000 
Methocel E3 Premium LV 2906 3 
Methocel E6 Premium LV 2906 6 
Methocel E15 Premium LV 2906 15 
Metolose 60SH 2910 50, 4000, 10 000 
Metolose 65SH 2906 50, 400, 1500, 4000 
Metolose 90SH 2208 100, 400, 4000, 15 000 
 
 
Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
 
Melting point:  
 Browns at 190-200°C; chars at 225-230°C, glass transition temperature is 
170-180°C. 
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Moisture content:   
 Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and 
relative humidity of the surrounding air.  
 
Solubility: 
 Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%) and ether but  its soluble in mixtures of 
ethanol and dichloromethane, mixtures of methanol and dichloromethane, mixtures 
of water and alcohol. Certain grades of hypromellose are soluble in aqueous acetone 
solutions, mixtures of dichloromethane and propan-2-ol and other organic solvents. 
 
Viscosity (dynamic):  
           A wide range of viscosity types are commercially available. Aqueous solutions 
are most commonly prepared, although hypromellose may also be dissolved in 
aqueous alcohols such as ethanol and propan-2-ol provided the alcohol content is 
less than 50% w/w.  
 
Stability and storage conditions: 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3-11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol-gel transformation upon 
heating and cooling, respectively. The gel point is 50-90°C, depending upon the 
grade and concentration of material. 
 
 
 
 
 
 
 
                              MICROCRYSTALLINE CELLULOSE: [26] 
Excipients Profile 
 
Dept of Pharmaceutics, Annai Veilankanni’s Pharmacy College , Chennai.  Page 26 
 
 
Nonproprietary Names:     
BP          : Microcrystalline cellulose 
JP           : Microcrystalline cellulose 
PhEur     : Cellulosum microcristallinum 
USPNF   : Microcrystalline cellulose 
 
Synonyms:  
        Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose;                        
E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
 
Chemical Name  :  Cellulose 
CAS Registry Number :  [9004-34-6] 
Molecular Weight  :  36, 000 
 
Functional Category:  
        Adsorbent;  suspending agent;  tablet and capsule diluent; tablet disintegrant. 
 
Description: 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs 
as a white, odorless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grades that have 
different properties and applications. 
   
Typical Properties: 
Density (bulk)        :            0.337 g/cm3; 
Density (tapped)    :            0.478 g/cm3; 
Density (true)         :            1.512–1.668 g/cm3 
Flowability             :            1.41 g/s 
Melting point         :            chars at 260–270°C. 
 
Specific surface area:           1.06–1.12 m2/g for Avicel PH-101; 
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                                               1.21–1.30 m2/g for Avicel PH-102; 
                                               0.78–1.18 m2/g for Avicel PH-200. 
                                               1.21–1.30 m2/g for Avicel PH-102; 
 
Moisture content:  
Typically less than 5% w/w. However, different grades may contain varying 
amounts of water. Microcrystalline cellulose is hygroscopic. (Avicel PH- 102= • 5.0) 
 
Solubility:  
Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, 
dilute acids, and most organic solvents. 
 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and directcompression processes.  Microcrystalline cellulose also has 
some lubricant and disintegrant properties that make it useful in tableting. 
 
Uses of microcrystalline cellulose 
1. Adsorbent 
2. Capsule binder/diluents 
3. Tablet disintegrants 
4. Tablet binder/diluents 
 
Stability and Storage Conditions:  
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
 
Incompatibilities:  
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
     
                                    MAGNESIUM STEARATE:[25]                            
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Nonproprietary names: 
BP : Magnesium stearate 
JP : Magnesium stearate 
PhEur : Magnesii stearas 
USPNF : Magnesium stearate  
Synonyms    :    Magnesium octa decanoate, Magnesium salt. 
Chemical name and CAS registry number 
Octa decanoic acid magnesium salt [557-04-0] 
Functional category : Tablet and capsule lubricant 
Empirical formula :   C36H70MgO4 
Molecular weight         :  591.3 
Structure  : 
                                         CH3 (CH2)16 COO                           
                                                                                      Mg    
                                         CH3 (CH2)16 COO 
Description: 
           It is a fine, white, precipitated or milled, impalpable powder of low bulk 
density and having a faint odor of stearic acid, characteristic taste.  
 Solubility: 
          It is insoluble in water, ethanol and ether. It can slightly soluble in warm 
ethanol and benzene.        
 Stability and storage conditions: 
  Stable, Store in a well closed container in a cool, dry place.                               
TALC:[25]                             
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Nonproprietary names: 
BP : Purified talc 
JP : Talc 
PhEur : Talcum 
USPNF : Talc 
Synonyms: 
 Purified chalk, altalc, powdered talc and soapstone 
Chemical name and CAS registry number: Talc [14807-96-6] 
Description: 
            A very fine, white to grayish white, impalpable, odorless crystalline 
powder,  
Unctuous, adheres readily to skin, soft to touch and free from granules. 
Empirical formula  :  Mg6 (Si2O5)4(OH)4 
Functional category: 
           Tablet, capsule it can use as a lubricant and diluents. During compression 
used as glidant and anticaking agent. 
Solubility:    
 Insoluble in water, organic solvents, dilutes acids and alkalis. 
Storage conditions:  
          Stable, Preserve in a well-closed container in a cool, dry place. 
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CARBOPOL -940[27] 
       Nonproprietary Names:  
         BP, PhEur and USP-NF  :      Carbomer. 
Synonyms:  
Acrypol; Acritamer; acrylic acid polymer; carbomera; Carbopol; carboxy 
polymethylene; polyacrylic acid; carboxyvinyl polymer; Pemulen; Tego 
Carbomer. 
Chemical Name:  
Polyacrylate – 1- cross polymer. 
Empirical Formula:  
Carbomers are synthetic high-molecular-weight polymers of acrylic acid that 
are crosslinked with either allyl sucrose or allyl ethers of pentaerythritol. 
Structural Formula: 
General Structure of Carbopol Polymers 
 
Description:  
Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a 
characteristic slight odor. 
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Typical Properties: 
 Density (bulk): 0.2 g/cm3 (powder); 0.4 g/cm3 (granular). 
 Density (tapped): 0.3 g/cm3 (powder); 0.4 g/cm3 (granular). 
 Dissociation constant (pKa): 6.0±0.5 
  Glass transition temperature: 100–105˚C. 
 Melting point: Decomposition occurs within 30 minutes at 260˚C. 
 pH: 2.5–4.0 for a 0.2% w/v aqueous dispersion. 
 Moisture content: 2.0%w/w maximum. 
 Specific gravity: 1.41  
 Viscosity of Carbomer 940 (0.5% w/v): 40,000-60,000 (mPa s). 
Solubility:   
Swellable in water and glycerin and, after neutralization, in ethanol (95%).   
Carbomers do not dissolve but merely swell to a remarkable extent, since they 
are three-dimensionally crosslinked microgels. 
Functional Category: 
Bioadhesive material; controlled-release agent; emulsifying agent; emulsion 
stabilizer; rheology modifier; stabilizing agent; suspending agent; tablet 
binder. 
 
Applications in Pharmaceutical Formulation: 
 
Use Concentration (%) 
Emulsifying agent 0.1 – 0.5
Gelling agent 0.5 – 2.0
Suspending agent 0.5 – 1.0
Tablet binder 0.75 – 3.0
Controlled-release 5.0 – 30.0
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agent
 
 
Safety: 
Carbomers are used extensively in nonparenteral products, particularly 
topical liquid and semisolid preparations. Grades polymerized in ethyl acetate 
may also be used in oral formulations. There is no evidence of systemic 
absorption of carbomer polymers following oral administration. 
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MATERIALS AND METHODS 
Table no-2 
INSTRUMENTS SUPPLIER/ MANUFACTURER 
Single pan analytical balance Sartorius 
Hot air oven Biotechnis – India 
    Tablet punching machine Karnavathi – 10 Station 
Hardness tester Pfizer tablet hardness tester 
Roche  friabilator Electrolab 
Dissolution apparatus Campbell electronics –Mumbai 
Disintegration apparatus Campbell electronics –Mumbai 
UV spectrophotometer 
Elico-SL 159 UV-Visible 
spectrophotometer, Japan 
            Vernier caliper Electro lab - Mumbai 
                                              
Table no-3:  Materials used 
MATERIAL SUPPLIER/ MANUFACTURER 
Cinitapride Chromo labs 
Corbopol   940 Lobachemie pvt. Ltd 
Micro crystalline cellulose SD fine chemicals 
HPMC k4m SD fine chemicals 
HPMC e15m Finar chemicals Ltd 
HPMC k100m Finar chemicals Ltd 
Magnesium stearate SD fine chemicals 
Talc SD Fine – Chem. ltd 
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                                                 METHODOLOGY 
PRELIMINARY STUDIES 
Determination of max: 
  Stock solution of 1mg/ml Cinitapride was prepared by dissolving 100mg 
of a drug in water  and diluted up to 100 ml with water . From this 1ml of 
solution is diluted with [0.1 N HCL] and make up to 100ml and max of the solution 
was found in the range from 200-400nm. The  max of the solution was found to be 
264nm. 
 Preparation of standard curve: pH1.2[28]  .  
 Stock solution of 1mg/ml Cinitapride was prepared by dissolving 100mg of a 
drug in water  and diluted up to 100 ml with water . From this 1ml of solution is 
diluted with [0.1 N HCL] and make up to 100ml to obtain concentration of 
1µg/ml.From the standard stock solution of Cinitapride appropriate aliquots of 
5,10,15,20,25and 30ml were pipetted out into 100ml volumetric flask and final 
volume was made with 0.1 N HCL,Absorbance spectra of each solution against 
0.1 N HCl as blank were measured at 264 nm using Elico-SL 159 UV-Visible 
spectrophotometer.   
FORMULATION OF FLOATING  TABLETS: 
POLYMER SELECTION: 
   Procedure: Trial batches of floating  tablets were prepared using 
different polymers [HPMC  k4m, HPMC k100m,HPMC e15m ];  different drug: 
polymer ratio  was used. Tablets prepared by direct compression technique and 
evaluated for floating lag time in HCL buffer (pH 1.2) medium. 
   Inference:  tablets prepared using polymers (HPMC k4m,HPMC 
k100m,HPMC e15m) showed best results in terms of floating lag time . Hence 
these polymers were selected  for the development of Cinitapride floating  tablets. 
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DRUG-EXCIPIENT COMPATABILITY STUDY BY FTIR: 
  IR spectra matching approach was used for detection of any possible 
chemical interaction between drug and polymers. A physical mixture  of drug 
and polymer was prepared and mixed with suitable quantity of potassium 
bromide. About 100mg of this mixture was compressed to form a transparent 
pellet using a hydraulic press at 6 tons pressure. It was then scanned from 4000 
to 400 cm-1 in FTIR spectrometer. The IR spectrum of the physical mixture was 
compared with those of pure drug and polymers; matching was done to detect 
any appearance or disappearance of peaks. 
FORMULATION DESIGN: 
Floating  tablets of  Cinitapride were prepared based on following design : 
•  Polymers          :  HPMC k4m,HPMC k100m  and HPMC e15m. 
• Swelling agent  :  Carbapol. 
• Filler                  :  Micro crystalline cellulose. 
Tablets were prepared by direct compression method. A total of 
9formulations (3 formulations based on HPMC k4m,3 formulation based on 
HPMC k100m& another 3 formulations based on HPMC e15m) were designed 
by varying the amounts of polymers at 3 levels (low, medium & high) using cross 
over design (as shown in Table-4).  
Table no-4: Composition of floating tablets 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Cintapride 2 2 2 2 2 2 2 2 2 
HPMC  
k4m 
40 60 80 - - - - - - 
HPMC 
e15m 
- - - 40 60 80 - - - 
HPMC 
k100m 
      40 60 80 
Carbopol940 10 10 10 10 10 10 10 10 10 
MCC 44 24 4 44 24 4 44 24 4 
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Mg.Stearete 3 3 3 3 3 3 3 3 3 
Talc 1 1 1 1 1 1 1 1 1 
 
F1:  formulation with  40%  hpmc k4m 
F2:  formulation with  60%  hpmc k4m 
F3:  formulation with  80%  hpmc k4m 
F4:  formulation with  40%  hpmc e15m 
F5:  formulation with  60%  hpmc e15m 
F6:  formulation with  80%  hpmc e15m 
F7:  formulation with  40%  hpmc k100m 
F8:  formulation with  60%  hpmc k100m 
F9:  formulation with  80%  hpmc k100m 
 
PREPARATION OF POWDER BLEND: 
The ingredients were accurately weighed and sifted through sieve #60, 
and then the materials except talc and magnesium stearate were blended using 
mortar and pestle for 10 min in an ascending order. Powder mixture then 
blended with talc and magnesium stearate for 5 min. 
EVALUATION OF POWDER BLEND: 
The prepared powder blends were subjected to evaluation as per the 
methods suggested in the Indian Pharmacopoeia like Angle of repose, Bulk 
density, Tap density, Compressibility index & Hausner’s ratio. 
Angle of repose:      
The angle of repose is the maximum angle formed between the surface of 
a pile of powder and horizontal surface. It is determined by the funnel method. A 
funnel was kept vertically at a specified height and the funnel bottom was closed. 
10 gm of sample powder was filled inside the funnel. Then funnel was opened to 
release the powder to form a smooth conical heap which just touches the tip of 
the funnel. From the powder cone, the radius of the heap (r) and the height of the 
heap (h) were measured. The angle of repose is represented as ‘ ’ and calculated 
using the following equation: 
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          Tan  = h/r                                          (1) 
            Table no-5: Flow properties and corresponding Angles of repose 
FLOW PROPERTY ANGLE OF REPOSE (DEGREES) 
Excellent 25-30 
Good  31-35 
Fair  36-40 
Passable 41-45 
Poor  46-55 
Very poor  56-65 
Very, very poor >66 
 
Bulk Density: 
The bulk densities of the powder blends were determined by transferring 
an accurately weighed 10 gm of sample powder to the graduated 50 ml 
measuring cylinder. The initial volume (bulk volume) was noted. The bulk 
density calculated using formula: 
        Bulk Density = Weight of Sample /  Bulk Volume                  (2) 
Tapped Density:  
An accurately weighed 10 gm of sample powder was transferred to the 
graduated 50ml measuring cylinder and placed on the tap density test apparatus. 
The apparatus was operated for a fixed number of taps (500 taps). The final 
volume (tapped volume) of the powder mass was noted. The tapped density 
calculated using formula: 
  Tapped Density = Weight of Sample / Tapped Volume              (3)       
Compressibility Index: 
The compressibility index is determined from the bulk volume and tapped 
volume of the powder. The basic method used for the determination of 
compressibility index is to measure the bulk volume and the final tapped volume 
after tapping until no change in volume occurs. It is represented in percentage. 
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  % Compressibility = (Tapped density - Bulk density) / Tapped density X 100           
(4) 
Table no-6: Scale of Flowability based on Compressibility Index 
COMPRESSIBILITY 
INDEX (%) 
FLOW 
CHARACTER 
• 10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Very, very poor 
 
Hausner’s Ratio:  
Hausner’s ratio is the ratio of bulk density to the tapped density of 
powder (or) initial volume of the powder mass to the final volume of the powder 
mass obtained after specified number of tapping. 
Table no-7: Scale of Flowability based on Hausner’s Ratio 
 
 
 
 
 
 
 
 
HAUSNER’S RATIO FLOW CHARACTER 
1-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
>1.60 Very, very poor 
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 Assay of Blend: 
Powder blend equivalent to 10 mg of Cinitapride was weighed and 
transferred to 100ml volumetric flask. Added 20ml of HCL buffer (pH 1.2) and 
sonicated for 10min.Then solution was filtered through 0.45 µm whatmann filter 
paper and made up to 100ml with HCL buffer (pH 1.2). 1ml of resultant solution 
was taken and diluted to 100ml with HCL buffer (pH 1.2) and the absorbance 
was measured at 264nm using UV spectrophotometer. 
COMPRESSION OF FLOATING TABLET: 
Weighed accurately about 100mg of the mixture blend and fed in 10 
station compression machine and compressed at 1.5N compression force using 
6mm concave punches. 
EVALUATION OF FLOATING  TABLET: 
Weight variation test: 
20 tablets were selected randomly and weighed. Average weight was 
calculated. Each tablet was weighed individually. Weight of the individual tablets 
was compared with the average weight and reported with standard deviation. 
Since the tablets weighed 80mg – 250mg, Indian Pharmacopoeia specifies that the 
tablets pass the test if not more than two of the individual weights deviate from 
the average weight by more than 7.5% 
 Table no-8: Weight variation limit as per Indian Pharmacopoeia 
 
Percentage deviation allowed under weight variation test 
Average weight of tablet Percentage deviation 
•  80mg 10% 
80-250mg 7.5% 
•  250mg 5% 
 
Thickness and diameter:  
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Thickness and diameter were measured during tablet compression using 
Vernier calliper. 
Hardness: 
Hardness of the tablets was measured using Pfizer tablet hardness tester. 
A sample of 6 tablets was randomly taken from each batch. The tablets were 
held vertically in between the jaws which were pressed with hand until the 
tablet broken. The reading was noted from the needle of pressure dial which 
may be expressed in kilograms. 
 
Friability: 
Friability is performed to evaluate the ability of tablet to withstand 
abrasions. Ten tablets were weighed and placed in the tumbling chamber which 
was rotated for 100 revolutions. The tablets were dedusted and again weighed.  
The loss in weight indicated the friability. 
  
              A-B                                                                   (5) 
    % Friability =            
     B 
 
Where A=Initial weight of tablet 
 B=Weight of tablet after 100 revolutions. 
 
Assay of tablet: [32] 
20 tablets were weighed and powdered. A quantity of the powder 
equivalent to 20 mg of  Cinitapride was accurately weighed. Added 20 ml of 
water and shaken for 10 minutes.  Then added 50 ml of methanol, shaken for a 
further 10 minutes, sufficient methanol was added to produce 100 ml and then 
filtered. 10 ml of the filtrate was diluted to 50 ml with methanol and the 
absorbance of the resulting solution was measured at the maximum at about 
264nm. The content of Cinitapride was calculated. 
 
I.P Limit: Tablets contain not less than 92.5 per cent and not more than 
107.5 per cent of the stated amount of Cinitapride.  
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COMPRESSION OF TABLETS 
Accurately weighed powder blend equivalent to 2mg of Cinitapride is fed in 10 
station compression machine , Round concave punches of 6mm diameter were 
used for compression. The tablets were compressed to a hardness of about 5 - 
6kg/cm2. 
 
In-vitro Dissolution: [29]  
Cinitapride release from different formulations was determined using a USP 
XXIII paddle apparatus 2 under sink condition. To simulate in-vivo condition 
the dissolution medium was selected as 900 ml  HCL buffer (pH 1.2) samples 
were withdrawn at 1st,2nd,3rd,6th,7th,9th and 12th hour time interval at 37 ± 0.2 °C. 
All experiments were done in triplicate and average values were taken. The 
formulations prepared were subjected to dissolution tests for 12 hrs. Samples 
were withdrawn at predetermined time intervals, filtered through 0.45µm 
Whatmann filter paper and replaced by an equal volume of dissolution medium. 
Absorbance of the diluted dissolution samples were determined by UV 
spectrophotometer at 264nm and drug content was calculated using calibration 
curve method. 
 
Dissolution test Conditions: 
Apparatus  : USP XXIII paddle apparatus 2. 
RPM   : 100. 
Temperature  : 37 ± 0.2 °C. 
Medium  : HCL (pH 1.2)  
Duration of test : 12 hrs. 
Sampling Interval : 1st,2nd,3rd,6th,7th,9th and 12th  
Sampling Volume : 10ml. 
 
Floating Behaviours: [30] 
Floating behaviour studies were carried out in a USP XXIII paddle 
apparatus 2 at a paddle speed of 100 rpm in 900 ml HCL buffer (pH 1.2) at 37 ± 
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0.2 °C. The parameters determined were; the time taken by the tablet to go 
upward and float on the surface (floating lag time), the time at which the tablet 
remained buoyant (floating duration) and were determined on the basis of 
visual inspection. 
  
DRUG RELEASE KINETICS: [31]  
To study the release kinetics, data obtained from in-vitro drug release 
studies were plotted in various kinetic models: zero order (Equation 6) as 
cumulative amount of drug released vs. time, first order (Equation 7)  
 
C = K0 t     (6) 
 
Where, 
  K0: is the zero-order rate constant expressed in units of 
concentration/time  
 t: is the time in hours.  
A graph of concentration vs. time would yield a straight line with a slope 
equal to K0 and intercept the origin of the axes. 
 
     LogC = LogCo• kt/2.303            (7) 
 
Where, 
  C0: is the initial concentration of drug,  
  K: is the first order constant, and t is the time. 
 
              Q = Kt1/2           (8) 
Where, 
   K: is the constant reflecting the design variables of the system  
t: is the time in hours. Hence, drug release rate is proportional to the 
reciprocal of the square root of time. 
 
 To evaluate the drug release with changes in the surface area and the 
diameter of the particles/tablets, the data were also plotted using the Hixson-
Crowell cube root law (Equation 9): 
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0 t3 Q -3 Q =kHC-t     (9) 
 
Where, 
Qt is the amount of drug released in time t,  
Q0 is the initial amount of the drug in the tablet, and 
KHC is the rate constant for the Hixson-Crowell rate equation, as the 
cube root of the percentage of drug remaining in the matrix vs. time. 
 
STABILITY STUDIES:  
The prepared formulations which showed best in vitro results was selected and 
kept for stability testing  for  90 days. The tablets were kept at 40± 2°C/ 
75%±5%RH in a stability chamber and samples were withdrawn at initial, 30 th, 
60 th and 90th day and evaluated for drug content, dissolution  study.  
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RESULTS 
 
PRELIMINARY STUDIES: 
Determination of max of  Cinitapride: 
  Cinitapride showed absorption maxima at 264 nm. 
Calibration curve of Cinitapride: 
Table no-9:  Standard Calibration Data of Cinitapride 
 
 
 
 
 
 
 
 
 
Concentration (µg/ml) Absorbance at 264nm 
5 0.102 
10 0.205 
15 0.309 
20 0.412 
25 0.520 
30 0.630 
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Fig.3:  Standard Calibration curve of Cinitapride in 0.1N HCL at 264nm
 
 
PRE-COMPRESSION EVALUATION: 
Evaluation of powder blend: 
Table no-10: Pre-compression parameters of powder blend 
 
Formulation Bulk 
Density(gm\ml)
Tapped 
Density(gm\ml)
Compressability 
Index 
Hausenr’s 
Ratio 
Angle 
Of 
Repose
F1 0.3 0.35 19 1.16 32.1 
F2     0.308 0.49   22.5 1.59 35.6 
F3   0.31            0.5   24.3 1.61 35 
F4 0.4 0.51  23.2 1.27 33.1 
F5    0.416 0.34  21.7   0.817 39.8 
F6  0.44 0.35   23.27 0.79 34 
F7  0.38 0.48 24.1 1.26 36.5 
F8   0.41  0.44  24.6    1.07     36 
F9   0.39  0.43  22.5   0.90     37.4 
 
 
 
 
R² = 0.999
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0
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Compatibility studies by FTIR: 
 
                  
                                                    
Fig.4: IR Spectra of Drug + HPMCk100m 
 
Table no-11: Characteristic peaks of IR spectra of Cinitapride 
Frequency (cm-1) Functional group specification 
2973 Aromatic –C-H- stretching 
1559 Secondary amine –NH- bending  
1464 CH- bending
1368 Primary alcohol –OH bending 
1296 Secondary alcohol -O-H stretching 
1075 C-O Stretching[ether] 
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Fig.5: IR Spectra of Drug + HPMC e15  
 
Fig.6: IR Spectra of Drug + MCC 
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Fig.7: IR Spectra of Drug + Magnesium Sterate 
 
 
Fig.8: IR Spectra of Pure Drug 
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Fig.9: IR Spectra of Drug + Carbapol 940 
 
  
Fig.10: IR Spectra of Drug + HPMC k4m 
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POST-COMPRESSION EVALUATION OF FLOATING TABLETS: 
 
Evaluation of physical parameters: 
 
Table no-12: Physical parameters of prepared tablets 
    
Formulation Avg.Wt 
(mg) 
Thickness 
(mm) 
Diameter(mm) Hardness 
(Kg\cm2) 
Friability
F1 100.2 2.8 6 5.5 0.11 
F2 101.1 2.6 6 5.4 0.06 
F3 100.6 2.5 6 5.6 0.14 
F4 100.1 2.8 6 6 0.04 
F5 100.8 2.7 6 5.1 0.14 
F6 100.1 2.6 6 5.4 0.06 
F7 100.4 2.6 6 5.5 0.16 
F8 99.4 2.6 6 5.5 0.41 
F9 101.6 2.65 6 5.4 0.02 
   
* mean ± standard deviation (SD). 
 
 
 
 
 
Evaluation of Floating Behaviours: 
Results and Discussion 
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Table no-13: Results of in-vitro floating behaviours 
 
Polymer Formulation 
code 
Floating lag 
time (sec) 
Buoyancy 
(hrs) 
HPMC k4m 
 
 
F1 120 Less than 12 
F2 180 More than12 
F3 280 Less than 12 
HPMC e15m      F4 110 More than12 
F5 90 More than12 
F6 67 Less than 12 
HPMC k100m F7 210 Less than 12 
F8 72 Less than 12 
F9 180 Less than12 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of In-vitro Drug Release: 
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Table no-14: Results of in-vitro drug release study of Cinitapride floating tablets 
 
 
Formulation 
code 
1st hr 2nd hr 3rd hr 6th hr 7th hr 9th hr 12th hr 
FI 17.87 22.67 29.21 55.37 63.65 77.61 96.36 
F2 17 20.92 27.46 56.24 67.58 79.79 98.54 
F3 22.23 28.34 33.13 66.27 76.3 85.89 95.48 
F4 19.18 25.72 30.95 63.65 73.68 81.09 89.82 
F5 24.41 30.08 35.31 70.63 77.17 90.69 99.41 
F6 18.31 25.28 33.57 62.78 70.63 78.91 95.48 
F7 21.8 28.77 37.06 68.45 78.04 83.27 92.43 
F8 13.95 19.18 25.72 48.83 57.99 71.94 82.84 
F9 41.85 53.19 63.22 75.86 86.76 92 93.3 
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Fig.11: Results of in-vitro drug release study of Cinitapride Floating Tablets 
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Table No-15: Results of drug release kinetics analysis 
 
Formulation 
code 
Zero-order First –order 
R2 R2 
F1 0.839 0.830 
F2 0.706 0.747 
F3 0.883 0.906 
F4 0.944 0.955 
F5 0.954 0.958 
F6 0.938 0.939 
F7 0.978 0.984 
F8 0.995 0.907 
F9 0.968 0.958 
 
 
 
 
 
 
 
 
STABILITY STUDIES:  
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Table no-16: Results of Parameters evaluated after 3 months stability study 
 
 
Parameters evaluated 
Formulation code 
F5 
Initial final 
Physical appearance - 
No 
change 
Assay (% drug content) 99.89 97.73 
Floating lag time (sec) 90 85 
Floating duration (hrs) >12 <12 
Cumulative % Drug 
Release (after 12hrs) 
99.41 98.56 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
PRELIMINARY STUDIES: 
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 Determination of max of Cinitapride: 
  A solution containing (10µg/ml) of Cinitapride was scanned in the range of 
200-400 nm. Cinitapride showed absorption maxima at 264 nm. 
 Calibration curve of Cinitapride: 
Calibration curve of Cinitapride showed good  linearity in the range of 5-
30µg/ml with  regression coefficient (R2) value of 0.9998 as shown in (Fig.3). 
PRE-COMPRESSION EVALUATION: 
Evaluation of powder blend: 
All the materials were properly mixed as per composition shown in (Table-4). 
For each designed formulation, blend of drug and excipients were prepared and 
subjected for pre-compression parameters like angle of repose, bulk density, tapped 
density, compressibility index and Hausner’s ratio. The obtained results were shown 
in (Table10). 
As a general guide, powders with angles of repose greater than 50° have 
unsatisfactory flow properties, whereas minimum angles close to 25° correspond to 
very good flow properties. The angle of repose ranged between 32.1˚ to 39.8˚, which 
indicates good flow propriety of powders.  
The bulk density and tapped density for all formulations were found to be in 
the range of 0.300 to 0.440 gm/cm3 and 0.340 to 0.510 gm/cm3 respectively, which 
indicates good packing character.  
The powder has a good flowability, when the Hausner’s ratio is lower than 
1.2, and when the value exceeds 1.2 it indicates poor flow. Compressibility is 
indirectly related to the relative flow rate, cohesiveness, and particle size of a 
powder. A compressible material will be less flowable, and powders with 
compressibility values greater than 20-21 % have been found to exhibit poor flow 
properties. The Hausner’s ratio and % Compressibility index was found to be in the 
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range of 0.79 to 1.59 and 19 % to 24 % respectively, which supports the fact that the 
formulations have good flow and compaction properties. 
All formulations exhibited good flow property and compressibility which is 
very essential for direct compression and hence tablets were prepared by using 
direct compression technology.  
Compatibility studies by FTIR: 
Drug polymer interaction was checked by comparing the IR spectra of pure 
drug with the IR spectra of physical mixtures of drug and excipients used. As shown 
in (Fig.4 to Fig.10).  
IR spectra matching approach was used for detection of any possible 
chemical interaction between drug and polymer. All the characteristic peaks of 
Cinitapride mentioned in (Table-11) were also found in the IR spectra of physical 
mixtures. 
Frequencies of functional groups of pure drug remained intact in physical 
mixtures containing different polymers; hence, there was no major interaction 
between the drug and excipients used in this study. 
 
COMPRESSION OF TABLETS: 
The floating tablets were prepared by direct compression technique. The 
target weight of the prepared tablet was 100mg. The desired hardness is between 5 - 
6 Kg/cm2. All the tablets were found to be uniform in size and shape and no 
processing problems were encountered during compression process. 
 
POST-COMPRESSION EVALUATION OF FLOATING TABLETS: 
 
Evaluation of physical parameters: 
The compressed tablets were evaluated for their weight variation, hardness, 
thickness, friability and content uniformity as per Indian pharmacopoeia [67] , and 
the results were shown in (Table-12).  
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All the compressed tablets passed the weight variation test. The mean 
thickness of the prepared tablets was found to be between 2.6 – 2.8mm. The mean 
hardness of the tablets ranged from 5.4 – 6.0 kg/cm2. Percentage friability ranged 
from 0.02 % to 0.16%. The drug content in all the prepared tablets complied with 
the Indian pharmacopoeia requirements, which was found to lie within the range of 
82.84to 99.41 %.  
All values of the physical parameters were found to be within the 
pharmacopoeial limits.   
Evaluation of Floating Behaviours: 
The parameters determined were; Floating Lag Time- the time taken by the 
tablet to go upward and float on the surface, Floating Duration- the time at which 
the tablet remained buoyant (determined on the basis of visual inspection); and the 
results were shown in (Table-13).  
 
Carbapol 940 was used as the Swelling agent. , the fluid permeated into the 
tablet, causing neutralization reaction to occur, which generates carbon dioxide 
(CO2). The swelling polymer traps the CO2 so generated and thus provides continued 
buoyancy. [30] 
 
The floating lag time was found to be in the range of 67 to 280 seconds. 
Formulations containing varying concentration of polymers (F-1,2,3,4,5,6,7,8 and 9) 
showed  buoyancy time of 12 hrs.  
Evaluation of In-vitro Drug Release: 
Cinitapride release from different formulations was determined in 900ml  
HCL buffer (pH 1.2) at 37 ± 0.2 °C. All experiments were done in triplicate and 
average values were taken. The dissolution data of formulations were shown in 
(Table-14). 
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It was observed that the particular concentration of polymer  HPMC e15m 
shows release  of drug over an extended period of time. Hence formulation (F5) were 
able to efficiently control Cinitapride release over a time period of 12 hrs.  
 
Carbopol-940  being highly swellable agent were able to swell to forms a 
thick viscous layer around the tablet. Since increases the diffusion path length and 
the drug diffusion tends to slow down and hence a reduction in drug release was 
observed. [65] 
DRUG RELEASE KINETICS:  
The in vitro drug dissolution data was analyzed for establishing kinetics of 
drug release. Model fitting was done [zero-order, first-order] . Interpretations of 
data were based on regression coefficient. The kinetic analysis data of all the 
formulations were shown in (Table-15). 
 
The R2 values obtained from zero order plot was found to be higher in 
comparison to first order plot which suggest that the drug release rate from the 
prepared tablets were in constant and controlled manner.  
 
STABILITY STUDIES:  
Accelerated stability studies were carried out according to ICH guidelines. 
Optimized formulations (F5) were sealed in aluminium packaging coated inside with 
polyethylene, and kept in a stability chamber at 40°C± 2°C and 75%±5% RH for 3 
months. At the end of the period, samples were analyzed for drug content, floating 
characteristics and   in-vitro drug release as shown in (Table-16). 
Stability study of optimized formulations revealed no significant change in 
physical appearance, drug content, floating lag time, floating duration as well as in-
vitro drug release.  And hence formulations were found to be stable at 40°C± 2°C 
and 75%±5% RH for 3 months.   
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SUMMARY 
The present study was aimed to formulate and evaluvate the  tablets 
containing Cinitapride based on floating  technique in order to increase gastric 
retention time for enhancing site-specific absorption in the stomach or upper parts 
of the small intestine as well as to produce controlled release of the drug for a longer 
time. Cinitapride shows pH dependent solubility and stability. It is more soluble & 
stable in acidic than alkaline pH. Hence, it will be beneficial to increase its gastric 
residence time. 
FORMULATION DESIGN: 
In this study; Cinitapride were prepared based on floating technique using: 3 
different polymers, HPMC k4m, HPMC e15m and HPMC k100m, Carbapol 940 as 
(Swelling agent) and Microcrystalline cellulose as (filler). A total of 9 formulations (3 
formulations in each polymer) were designed by varying the amounts of polymer  at 
3 levels (low, medium & high) using cross over design.  
PRE-COMPRESSION STUDIES: 
The prepared powder blends of all the 9 formulations were evaluated for pre-
compression parameters like angle of repose, bulk density, tapped density, 
compressibility index and Hausner’s ratio. The results obtained from these studies 
showed that the prepared blends were having satisfactory fluidity and 
compressibility; hence tablets can be prepared by direct compression method.  
IR spectra matching approach was used for detection of any possible 
chemical interaction between drug and polymers. This study revealed that there was 
no major interaction between the drug and excipients used. 
 
COMPRESSION OF TABLETS: 
The floating tablets were prepared by direct compression technique at a 
compression force (1.5N) in a concave punches (6mm size). The target weight of the 
prepared tablet was 100mg. The desired hardness is between 5-6Kg/cm2. All the 
Summary  
 
Dept of Pharmaceutics, Annai Veilankanni’s Pharmacy College , Chennai.  Page 61 
 
tablets were found to be uniform in size and shape and no processing problems were 
encountered during compression process. 
POST-COMPRESSION STUDIES: 
The compressed tablets were evaluated for their weight variation, hardness, 
thickness, friability and content uniformity as per Indian pharmacopoeia and the 
results were found to be within the prescribed limits. 
Floating behaviour studies were carried out in a USP XXIII paddle 
apparatus 2 at a paddle speed of 100 rpm in 900 ml HCL buffer (pH 1.2) at 37 ± 0.2 
°C. The parameters determined were; (Floating Lag Time, Floating Duration ). 
Floating lag time for all formulations were found to be less than 5min. Formulations 
containing varying concentration of polymer showed buoyancy time of 12hrs.  
Cinitapride release from different formulations was determined using a USP 
XXIII paddle apparatus 2 at a paddle speed of 100 rpm in 900 ml HCL buffer (pH 
1.2) at 37 ± 0.2 °C under sink condition for 12 hrs. In this study, it was observed that 
the medium concentration of polymer [HPMC e15m] in Formulation (F5) were able 
to efficiently control Cinitapride release over a time period of 12 hrs. 
The in vitro drug dissolution data obtained were plotted in various kinetic 
models for establishing kinetics of drug release. Zero order plot suggest that the 
drug release rate from the prepared tablets were in constant and controlled manner, 
for formulation (F5). 
Accelerated stability studies were carried out for optimized formulation (F5) 
in a stability chamber at 40°C±2°C and 75%±5% RH for 3 months. The study 
revealed no significant change in physical appearance, drug content, floating lag 
time, floating duration as well as in-vitro drug release.  And hence formulations 
were found to be stable. 
 
 
 
                   Conclusion 
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CONCLUSION 
 
Drug absorption in the gastrointestinal tract is a highly variable process 
and prolonging gastric retention of the dosage form extends the time for drug 
absorption. Gastro-retentive floating drug delivery systems have emerged as an 
efficient means of enhancing the bioavailability and controlled delivery of drugs 
that exhibit absorption window, low bioavailability and extensive first pass 
metabolism. 
  
In the present work floating tablets have been prepared incorporating a 
highly soluble   anti-ulcer drug Cinitapride using polymers like (HPMC 
k4m,HPMC e15m and HPMC k100m). swelling agent  (Carbapol 940) was used 
to keep the tablets floating over the simulated gastric fluid (pH 1.2) for more 
than 12 hrs. All the formulations showed floating lag time less than 5 min. 
Microcrystalline cellulose is used as a filler. The drug release mechanisms for 
these formulations were confirmed as zero-order release. The formulations (F5) 
were selected as an optimized formulations because it gave the best results in 
terms of the required in-vitro buoyancy as well as drug release in a sustained 
release manner and also were found to be stable under the stability conditions. 
 
Thus the results of the current study clearly indicate, a promising potential of the 
floating tablet as an alternative to conventional dosage form, further clinical 
studies are needed to assess the utility of this system for patients suffering from 
Gastro-esophageal reflux disease, Non-ulcer dyspepsia.  
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